A Novel CIP2A and BCL-XL Clinical Diagnostic Toolkit to Predict Disease Progression and Treatment-Free Remission in Chronic Myeloid Leukaemia. This evidence concerns the gene CIP2A and chronic myelogenous leukemia, BCR-ABL1 positive.